Clinical trials: Angiography
Contrast Enhanced X-ray Based Examination
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
This is an observational study in which patient data from the past of people who received Ultravist prior to an X-ray based scan are studied.
- Trial name
- NCT05428397
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- Germany
- Volunteers
- 152,233 people
- Sponsor
- Bayer
Ischemic Heart Disease
Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography
The purpose of this study is to verify the efficiency of the HyperQ technology compared with standard ECG analysis in detecting exercise induced ischemia in women who are referred to coronary angiography.
- Trial name
- NCT00850486
- Testing
- Exercise test with HyperQ technology
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- BSP Biological Signal Processing Ltd.
Diagnostic Imaging
Magnevist Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Magnevist at a dose of more than 0.2 ml/kg for MR angiography of peripheral…
- Trial name
- NCT01376739
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- Japan
- Volunteers
- 2,051 people
- Sponsor
- Bayer
Coronary Artery Disease, Atherosclerosis
The Lipid-Rich Plaque Study
The purpose of this study is to enhance medical knowledge of the causes of future coronary problems. Many studies in patients who have already experienced a coronary problem point to the danger associated with plaques that are…
- Trial name
- LRP (NCT02033694)
- Testing
- NIRS-IVUS Imaging (TVC Imaging System)
- Where
- 41 sites in United States, Italy and 4 more
- Volunteers
- 1,563 people
- Sponsor
- Infraredx
Magnetic Resonance Imaging
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has already been approved for application in adults, will be investigated in children and adolescents.
- Trial name
- NCT00468819
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- Bayer
Chronic Coronary Syndrome, Coronary Artery Disease
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and…
- Conditions
- Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- FOCUS DL (NCT06186336)
- Testing
- Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- GE Healthcare
Angiocardiography
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good…
- Trial name
- TRUST (NCT01206257)
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- China
- Volunteers
- 17,513 people
- Sponsor
- Bayer
Magnetic Resonance Imaging, Magnetic Resonance Angiography
GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients
Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with Gadovist®.
- Trial name
- GARDIAN (NCT01095081)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 20 sites in Bosnia and Herzegovina, Canada and 18 more
- Volunteers
- 23,775 people
- Sponsor
- Bayer